Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $6.42, marking a +1.58% move from the previous day.
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?
The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.
1 Artificial Intelligence (AI) Stock That Could Soar in 2025
The artificial intelligence (AI) field has been grabbing many headlines on Wall Street in the past two years. Will this trend continue in 2025?
Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The recent acquisition of Exscientia strengthens Recursion's pipeline and partnerships, potentially delivering up to $20 billion in milestone payments from collaborations with pharma giants. Despite unimpressive clinical trial results, the company's innovative platform and strategic partnerships justify a "Buy" rating for long-term, high-risk-tolerant investors.
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.43 per share a year ago.
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
In an environment where the typical small biotech name is riskier than not, this one is curiously different.
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $6.40, representing a +1.27% change from its previous close.
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.68, signifying a -0.89% move from its prior day's close.
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
This company stands to benefit from a shifting pharmaceutical industry landscape.
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
Recursion Pharmaceuticals (RXRX) reachead $6.36 at the closing of the latest trading day, reflecting a +0.47% change compared to its last close.
Cathie Wood Is Betting on This AI Stock: Is It a Buy?
Wood has a stake in this stock, but it's hardly an "all-in" bet.
